SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

NCT04287179 on ClinicalTrials.gov · last registry update 2022-02-03

Withdrawn before anyone was enrolled. Its estimated completion date, 16 November 2020, has passed with no update to the record. Primary outcome, as filed: Change in glycosylated haemoglobin (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 0
Started: 2020-03-09
Primary completion: 2020-11-16 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in glycosylated haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.